Preparing for an uncertain respiratory season
icon-infectious-disease-testing
Syndromic testing

Preparing for an uncertain respiratory season

As COVID-19 public health measures are reduced, influenza-like illnesses (ILIs) and COVID-19 will converge this respiratory season. Many regions in the U.S. have seen interseasonal increases in common respiratory pathogens (1–3). Similar symptomology between these pathogens and SARS-CoV-2, rising cases and the high risk of co-infections will likely present exceptional challenges to healthcare systems.

Diagnostic approaches using rapid molecular testing may help alleviate this burden. The Centers for Disease Control and Prevention has recommended the use of multiplex testing while COVID-19 and the flu are co-circulating (4). Highly multiplexed testing, commonly known as syndromic testing, can detect and differentiate >20 bacterial and viral pathogens in around one hour.

icon-infectious-disease-testing
Don’t miss out on the latest news this respiratory season

Adopting a syndromic diagnostic approach to serve the community during COVID-19

When COVID-19 struck in Northwest Indiana, USA, CEO and president of Great Lakes Labs, Michelle Volk, knew that she wanted to help. She placed her trust in the QIAstat-Dx system to test for a wide range of pathogens, not just SARS-CoV-2, to help provide fast answers and peace of mind to her community.

Don’t just test for SARS-CoV-2 this season

In this webinar, QIAGEN Chief Medical Officer Dr. Davide Manissero discusses the role of syndromic testing during the ongoing COVID-19 pandemic. He also addresses the importance of time to diagnosis and potential for co-infections during respiratory season.

Don’t just test for SARS-CoV-2 this season
Learn more about the QIAstat-Dx Respiratory SARS-CoV-2 Panel
* Enterovirus and Rhinovirus are both detected, but not differentiated, with the QIAstat-Dx Respiratory SARS-CoV-2 Panel.

Learn more about the QIAstat-Dx Respiratory SARS-CoV-2 Panel

To support the efforts for accessible testing to meet the demands of the COVID-19 outbreak, QIAGEN developed the QIAstat-Dx Respiratory SARS-CoV-2 Panel. This version of our multiplex syndromic cartridge detects and differentiates* 21 respiratory targets, including SARS-CoV-2 from nasopharyngeal swabs (NPS) eluted in universal transport media (UTM).

icon-callout-help
Ready to learn how syndromic testing with QIAstat-Dx can benefit your institution?
*Some features require a QIAstat-Dx Connectivity plan; flexible plans are available to meet your lab’s needs 

References
  1. Hodjat, P., Christensen, P.A., Subedi, S., Bernard, D.W., Olsen, R.J. and Long, S.W. (2021) The rapid reemergence of seasonal respiratory viruses in Houston, Texas, after relaxing COVID-19 restrictions. medRxiv. doi: https://doi.org/10.1101/2021.05.27.21257940
  2. Centers for Disease Control and Prevention Weekly U.S. Influenza Surveillance Report https://www.cdc.gov/flu/weekly/index.htm
  3. Centers for Disease Control and Prevention Increased Interseasonal Respiratory Syncytial Virus (RSV) Activity in Parts of the Southern United States https://emergency.cdc.gov/han/2021/han00443.asp
  4. Centers for Disease Control and Prevention Testing Guidance for Clinicians When SARS-CoV-2 and Influenza Viruses are Co-circulating https://www.cdc.gov/flu/professionals/diagnosis/testing-guidance-for-clinicians-hospitaized.htm

The QIAstat-Dx Analyzer is intended for in vitro diagnostic use.

The QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use.

  • This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories;
  • This product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and
  • This emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetics Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declarations is terminated or authorization is revoked sooner.
X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.
Confirm